Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?

Published on Sep 1, 2018in European Journal of Cancer6.68
· DOI :10.1016/j.ejca.2018.04.015
Maximiliano Gelli4
Estimated H-index: 4
Janina F.L. Huguenin1
Estimated H-index: 1
+ 8 AuthorsDiane Goéré34
Estimated H-index: 34
Abstract Introduction Over the last 20 years, complete cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) dramatically increased the survival of patients with colorectal peritoneal metastases (CRPM). However, despite better knowledge of the disease, around 70% of patients relapse after CRS with HIPEC. This study was designed to analyse the pattern of recurrence and the outcomes of different treatment modalities. Methods Patients relapsing after CRS plus HIPEC for CRPM were selected from a prospective database. The impact of iterative curative-intent treatments was analysed using Kaplan–Meier estimates and multivariate Cox regression models. Results Between April 1993 and December 2014, 190 of 274 (69%) patients previously treated by CRS plus HIPEC developed relapse, as an isolated peritoneal recurrence (31%), isolated distant recurrence (35%), or multisite recurrence (34%). The curative-intent treatment rate was 48% for isolated peritoneal recurrences, 49% for isolated distant recurrences and 22% for multisite recurrences (p = 0.002). From the diagnosis of relapse, 3- and 5-year overall survival were 77% and 46% after curative-intent treatment and 14% and 4.7% after non-curative treatment, with median survival of 59.7 and 18.3 months (log-rank p  Conclusions Iterative curative-intent treatment can be performed in up to 40% of patients with relapse after CRS and HIPEC for CRPM, and is associated with prolonged survival in selected patients.
  • References (39)
  • Citations (1)
📖 Papers frequently viewed together
26 Citations
37 Citations
10 Authors (Daniel M. Labow, ..., Vaagn Andikyan)
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1T.A. Bin Traiki (KSU: King Saud University)H-Index: 1
#2Oliver M. Fisher (UNSW: University of New South Wales)H-Index: 7
Last. David L. Morris (UNSW: University of New South Wales)H-Index: 65
view all 10 authors...
Abstract Purpose To analyze the outcomes of patients developing pulmonary metastases (PM) following cytoreductive surgery (CRS) and perioperative intra-peritoneal chemotherapy (IPC) for colorectal cancer (CRC) with peritoneal carcinomatosis. Patients and methods A retrospective analysis of patients undergoing CRS/IPC for CRC from 1996 to 2016 was performed. Lung-specific disease-free and patient overall survival was analyzed. Patients undergoing percutaneous lung ablative therapy (PLAT) for PM w...
1 CitationsSource
#1Guillaume PassotH-Index: 22
#2Delphine VaudoyerH-Index: 13
Last. Olivier GlehenH-Index: 46
view all 10 authors...
Abstract To determine whether a perioperative, standardized clinical pathway could impact the failure-to-rescue rate after cytoreductive surgery (CRS) for peritoneal carcinomatosis (PC) in a tertiary center. Morbidity and mortality remain significant after CRS for PC. Clinical pathways have been associated with better outcomes after surgery. The failure-to-rescue rate is a useful metric for evaluating quality in surgery. This study included 666 patients that received CRS for PC between 2009 and ...
15 CitationsSource
#1Universe LeungH-Index: 6
#2Mithat GonenH-Index: 105
Last. Michael I. D’AngelicaH-Index: 70
view all 7 authors...
Objective:The aim of the study was to evaluate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic disease (EHD), and to define prognostic factors.Background:There is increasing evidence to support resection of liver metastases and concurrent EHD in selected pa
30 CitationsSource
#1Jan Franko (Mercy Medical Center (Baltimore, Maryland))H-Index: 6
#2Qian D Shi (Mayo Clinic)H-Index: 24
Last. Axel F Grothey (Mayo Clinic)H-Index: 61
view all 20 authors...
Summary Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer without peritoneal involvement. Here we further investigated the effect of the number and location of metastases in patients receiving first-line systemic chemotherapy. Methods We analysed individual patient data for previously untreated patients enrolled in 14 phase 3 randomised trials done between 1997 and 2008. Trials were included if ...
88 CitationsSource
Combining chemotherapy and targeted therapies has resulted in an enhanced survival in metastatic colorectal cancer (mCRC) patients. However, the result of this palliative treatment in patients with metachronous peritoneal carcinomatosis (PC) remains unknown. The current population-based study aims to investigate the use and effect of palliative systemic treatment in patients with metachronous PC of colorectal origin. Data on metachronous PC were collected between 2010 and 2011 for all patients w...
7 CitationsSource
#2Simon W. NienhuijsH-Index: 29
Last. I.H.J.T. de HinghH-Index: 36
view all 7 authors...
Abstract Introduction The optimal treatment for peritoneal carcinomatosis (PC) of colorectal origin is a combination of cytoreductive surgery and intraperitoneal chemotherapy (CRS + IPC). Although 5-year survival rates of up to 40% have been reported, recurrent disease remains common and is estimated to be a strong negative prognostic factor for survival. This systematic review elaborates on the incidence of recurrent disease and the possibilities to prevent and treat recurrence. Methods Two sea...
14 CitationsSource
#1Jean M. Butte (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 13
#2Mithat Gonen (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 105
Last. Michael I. D’Angelica (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 70
view all 10 authors...
Purpose Patients with recurrence after complete resection of colorectal liver metastases (CLM) are considered for repeat resection as a potential salvage therapy (PST). However, outcomes for this approach are not well defined. We sought to analyze the natural history of recurrence and PST in a large cohort of patients with long-term follow-up.
34 CitationsSource
#1Dominique EliasH-Index: 82
#2Matthieu FaronH-Index: 9
Last. Diane GoéréH-Index: 34
view all 9 authors...
PURPOSE: To analyze and compare survival in patients operated for colorectal liver metastases (LM) with that in patients optimally resected for peritoneal metastases (PM). PATIENTS AND METHODS: This study concerns 287 patients with LM and 119 patients with PM treated with surgery plus chemotherapy between 1993 and 2009, excluding patients presenting both LM and PM. RESULTS: Mortality (respectively, 2.7% and 4.2%), morbidity (respectively, 11% and 17%), and 5-year overall survival (OS) rates (res...
43 CitationsSource
#1Rona Yaeger (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
#2Andrea Cercek (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 22
Last. Leonard Saltz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 103
view all 14 authors...
BACKGROUND BRAF mutations occur in 5% to 11% of patients with metastatic colorectal cancer (mCRC) and have been associated with poor prognosis. The current study was undertaken to determine the clinicopathologic characteristics, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) mutation frequency, and outcomes after metastasectomy in patients with BRAF-mutant mCRC. METHODS Data from 1941 consecutive patients with mCRC who underwent KRAS/BRAF mutation testing betwee...
78 CitationsSource
#1H.J. BraamH-Index: 10
Last. Bert van RamshorstH-Index: 38
view all 7 authors...
Background and Objectives CytoReductive Surgery (CRS) combined with Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) has an established role in the treatment of peritoneally metastasized colorectal cancer. The aim of the study was to describe the recurrence patterns and to evaluate treatment options and related survival. Methods Patients treated with CRS + HIPEC in two tertiary referral centers between April 2005 and March 2013 were analyzed retrospectively. The prognostic value of several para...
26 CitationsSource
Cited By1
#2Aurélie Fratti (French Institute of Health and Medical Research)
Last. Elise Jacquin (French Institute of Health and Medical Research)H-Index: 2
view all 14 authors...
Background We have previously shown that 5-fluorouracil (5-FU) selectively kills myeloid-derived suppressor cells (MDSCs) and activates NLRP3 (NOD-leucine rich repeat and pyrin containing protein 3) inflammasome. NLRP3 activation leads to caspase-1 activation and production of IL-1β, which in turn favors secondary tumor growth. We decided to explore the effects of either a heat shock (HS) or the deficiency in heat shock protein (HSP) 70, previously shown to respectively inhibit or increase NLRP3...
#1Linda Aagaard Rasmussen (AU: Aarhus University)H-Index: 5
#2Henry Jensen (AU: Aarhus University)H-Index: 8
Last. Peter Vedsted (AU: Aarhus University)H-Index: 38
view all 6 authors...
Background The organisation of cancer follow-up is under scrutiny in many countries, and general practice is suggested to become more involved. A central focus is timely detection of recurring previous cancer and new second primary cancer. More knowledge on the patient pathway before cancer recurrence and second primary cancer is warranted to ensure the best possible organisation of follow-up. We aimed to describe the healthcare utilisation in the year preceding a diagnosis of cancer recurrence ...
#1Jean Marc PhelipH-Index: 8
#2David TougeronH-Index: 15
Last. Olivier BouchéH-Index: 54
view all 15 authors...
Abstract Introduction This document is a summary of the French intergroup guidelines regarding the management of metastatic colorectal cancer (mCRC) published in January 2019, and available on the French Society of Gastroenterology website (SNFGE) ( ). Methods This collaborative work was realized by all French medical and surgical societies involved in the management of mCRC. Recommendations are graded in three categories (A, B and C), according to the level of evidence found in the...
7 CitationsSource